Program
apremilast
Also written as “Apremilast”, “Apremilast 20mg” and “Apremilast 30mg”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Behcet Syndrome · Arthritis, Juvenile · COVID-19, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 464 open or running | phase 4since Apr 3, 2015 | Apr 2, 2007 | Jan 10, 2027phase 1 · NCT07908641 |
| Boehringer Ingelheim | 10 open or running | phase 1since Mar 22, 2021 | Mar 22, 2021 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 3since Oct 10, 2023 | Oct 10, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 34 studies since Apr 2, 2007.
- Apr 25, 2019Phase 3 study in Plaque PsoriasisAmgen · NCT03930186 · 152 enrolled · Germany, Japan
- Aug 13, 2019Phase 2 study in PsoriasisAmgen · NCT04057937 · 90 enrolled · Japan
- Nov 21, 2019Phase 3 study in PsoriasisAmgen · NCT04175613 · 160 enrolled · United States, Belgium, Canada and more
- Aug 24, 2020Phase 3 study in Behcet SyndromeAmgen · NCT04528082 · 60 planned · France, Greece, Israel and more
- Oct 14, 2020Phase 3 study in COVID-19Amgen · NCT04590586 · 515 enrolled · United States, Argentina, Brazil and more
- Mar 16, 2021Phase 3 study in Arthritis, JuvenileAmgen · NCT04804553 · 60 planned · Belgium, France, Germany and more
- Mar 22, 2021Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT04811573 · 20 enrolled · Germany
- Dec 14, 2021Phase 3 study in PsoriasisAmgen · NCT05174065 · 176 enrolled · Japan
- Sep 20, 2022Phase 3 study in Plaque PsoriasisAmgen · NCT05565560 · 21 enrolled · Japan
- Mar 8, 2023Phase 3 study in Behcet SyndromeAmgen · NCT05767047 · 48 planned · Greece, Israel, Spain and more
- Oct 10, 2023Humanis Saglık Anonim Sirketi's first study: phase 3 study in PsoriasisNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06084663 · 36 enrolled · India
- Oct 12, 2023Phase 3 study in Plaque PsoriasisAmgen · NCT06088199 · 51 enrolled · United States
- Nov 3, 2023Phase 3 study in Plaque PsoriasisAmgen · NCT06122649 · 203 enrolled · China
- Oct 26, 2026Phase 1 study in PsoriasisAmgen · NCT07908641 · 114 planned
Ahead
- Jan 10, 2027Primary completion: phase 1 study in PsoriasisAmgen · NCT07908641
- Mar 21, 2028Primary completion: phase 3 study in Arthritis, JuvenileAmgen · NCT04804553
- Feb 7, 2030Primary completion: phase 3 study in Behcet SyndromeAmgen · NCT04528082
- Mar 17, 2036Primary completion: phase 3 study in Behcet SyndromeAmgen · NCT05767047
TargetBeta
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07908641Psoriasis | 1 | Not yet recruiting | Amgen | Jan 10, 2027 | 114 |
| NCT06122649Plaque Psoriasis · China | 3 | Completed | Amgen | Feb 28, 2025 | 203 |
| NCT06088199Plaque Psoriasis · United States | 3 | Completed | Amgen | Aug 12, 2026 | 51 |
| NCT06084663Psoriasis · India | 3 | Completed | Humanis Saglık Anonim Sirketi | Feb 25, 2023 | 36 |
| NCT05767047Behcet Syndrome · Greece, Israel, Spain and more | 3 | Recruiting | Amgen | Mar 17, 2036 | 48 |
| NCT05565560Plaque Psoriasis · Japan | 3 | Completed | Amgen | Nov 20, 2025 | 21 |
| NCT05174065Psoriasis · Japan | 3 | Completed | Amgen | Aug 19, 2023 | 176 |
| NCT04811573Healthy · Germany | 1 | Terminated | Boehringer Ingelheim | Aug 18, 2021 | 20 |
| NCT04804553Arthritis, Juvenile · Belgium, France, Germany and more | 3 | Recruiting | Amgen | Mar 21, 2028 | 60 |
| NCT04590586COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Amgen | Aug 3, 2021 | 515 |
| NCT04528082Behcet Syndrome · France, Greece, Israel and more | 3 | Recruiting | Amgen | Feb 7, 2030 | 60 |
| NCT04175613Psoriasis · United States, Belgium, Canada and more | 3 | Completed | Amgen | Oct 30, 2025 | 160 |
| NCT04057937Psoriasis · Japan | 2 | Completed | Amgen | Jan 18, 2021 | 90 |
| NCT03930186Plaque Psoriasis · Germany, Japan | 3 | Completed | Amgen | May 8, 2020 | 152 |
| NCT03783026Arthritis, Psoriatic · United States, Austria, Belgium and more | 4 | Completed | Amgen | Oct 26, 2021 | 123 |
| NCT03777436Psoriasis · United States, Belgium, Canada and more | 3 | Completed | Amgen | Sep 23, 2021 | 289 |
| NCT03774875Psoriasis · France, Germany, Italy and more | 4 | Completed | Amgen | Feb 1, 2021 | 277 |
| NCT03747939Arthritis, Psoriatic · United States, Austria, Belgium and more | 4 | Completed | Amgen | Dec 19, 2022 | 310 |
| NCT03721172Psoriasis · United States, Canada | 3 | Completed | Amgen | Mar 6, 2020 | 595 |
| NCT03701763Psoriasis · United States, Belgium, Canada and more | 3 | Completed | Amgen | Apr 25, 2022 | 245 |
| NCT03123471Psoriasis · United States, Canada | 3 | Completed | Amgen | Aug 13, 2018 | 303 |
| NCT02802735Pharmacokinetics · Korea, Republic of | 1 | Completed | Amgen | Aug 5, 2016 | 28 |
| NCT02777554Healthy Volunteers · United States | 1 | Completed | Amgen | Nov 22, 2016 | 144 |
| NCT02641353Healthy Volunteers · United States | 1 | Completed | Amgen | Feb 27, 2016 | 34 |
| NCT02576678Psoriasis · United States, Canada, Germany and more | 2 | Completed | Amgen | Sep 4, 2017 | 42 |
| NCT02425826Parapsoriasis · United States | 4 | Completed | Amgen | Feb 12, 2016 | 221 |
| NCT02307513Behcet Syndrome · United States, France, Germany and more | 3 | Completed | Amgen | Sep 25, 2017 | 207 |
| NCT02289417Colitis, Ulcerative · United States, Australia, Bulgaria and more | 2 | Completed | Amgen | Sep 25, 2017 | 170 |
| NCT02087943Dermatitis, Atopic · United States, Canada, Japan | 2 | Completed | Amgen | Oct 2015 | 191 |
| NCT01925768Arthritis, Psoriatic · United States, Australia, Canada and more | 3 | Completed | Amgen | Feb 25, 2015 | 219 |
| NCT01988103Psoriasis · Japan | 2 | Completed | Amgen | Nov 20, 2014 | 254 |
| NCT01690299Psoriasis · United States, Australia, Belgium and more | 3 | Completed | Amgen | Jul 3, 2014 | 250 |
| NCT01634191Healthy Volunteer · United States | 1 | Completed | Amgen | Mar 1, 2012 | 36 |
| NCT01634178Healthy Volunteer · United States | 1 | Completed | Amgen | Mar 1, 2012 | 46 |
| NCT01583374Spondylitis, Ankylosing · United States, Australia, Austria and more | 3 | Completed | Amgen | Feb 24, 2014 | 490 |
| NCT01561963Healthy Subjects · United States | 1 | Completed | Amgen | Apr 1, 2012 | 21 |
| NCT01307423Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Amgen | Feb 21, 2013 | 529 |
| NCT01285310Arthritis, Rheumatoid · United States, Czechia, Poland and more | 2 | Terminated | Amgen | Feb 21, 2012 | 237 |
| NCT01232283Plaque Psoriasis · United States, Austria, Canada and more | 3 | Completed | Amgen | Mar 15, 2012 | 413 |
| NCT01212770Arthritis, Psoriatic · United States, Australia, Canada and more | 3 | Completed | Amgen | Aug 21, 2012 | 505 |
| NCT01212757Arthritis, Psoriatic · United States, Belgium, Bulgaria and more | 3 | Completed | Amgen | Jul 26, 2012 | 488 |
| NCT01172938Arthritis, Psoriatic · United States, Australia, Austria and more | 3 | Completed | Amgen | Apr 27, 2012 | 504 |
| NCT00866359Behcet Syndrome · United States, Turkey | 2 | Completed | Amgen | May 1, 2012 | 111 |
| NCT00773734Psoriasis · United States, Canada | 2 | Completed | Amgen | Aug 1, 2009 | 352 |
| NCT00606450Psoriasis · Canada, Czechia, Germany | 2 | Completed | Amgen | Feb 1, 2007 | 260 |
| NCT00604682Psoriasis · United States | 2 | Completed | Amgen | Oct 1, 2005 | 19 |
| NCT00521339Psoriasis · United States | 2 | Completed | Amgen | Apr 1, 2009 | 31 |
| NCT00456092Arthritis, Psoriatic · Belgium, Canada, Germany and more | 2 | Completed | Amgen | May 9, 2009 | 204 |
How it is read
Names in the registry
- “Apremilast”, 31 entries
- “Apremilast 20mg”, 6 entries
- “Apremilast 30mg”, 5 entries
- “Apremilast (CC-10004)”, 3 entries
- “Apremilast 30 mg”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 18 studies
- Arthritis, Psoriatic, 12 studies
- Behcet Syndrome, 4 studies
- Arthritis, Juvenile, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.